2020
CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer
Nagaya N, Lee G, Horie S, Kim I. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer. Frontiers In Molecular Biosciences 2020, 7: 579874. PMID: 33195424, PMCID: PMC7593595, DOI: 10.3389/fmolb.2020.579874.Peer-Reviewed Original ResearchLymph node metastasisPrimary prostate cancerChemokines/receptorsMetastatic prostate cancerNode metastasisProstate cancerReceptor expressionMetastatic sitesChemokine/receptor axisMultivariate logistic regression analysisLog-rank test resultsLogistic regression analysisCancer Genome AtlasBone metastasesIndependent predictorsLymph nodesPostoperative recurrenceDistant metastasisCXCL10 expressionMRNA expression dataReceptor axisMetastasisTeam databaseLow expressionCancer progression
2019
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerDDR pathway alterationProstate cancerPathway alterationsMetastatic castration-resistant prostate cancerSerum prostate-specific antigenHigh-risk diseaseMetastatic prostate cancerLower overall survivalPathway gene mutationsProstate-specific antigenPotential therapeutic targetUnited States National Cancer InstituteNational Cancer InstituteCRPC patientsCancer Genome AtlasOverall survivalSimilar incidenceTumor stageUnivariate analysisCancer InstituteTherapeutic targetSpecific antigenPARP inhibitorsPathway status